KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Edwards Lifesciences (EW) Long-Term Debt Repayments (2016 - 2022)

Edwards Lifesciences (EW) has 12 years of Long-Term Debt Repayments data on record, last reported at $100000.0 in Q4 2022.

  • For Q4 2022, Long-Term Debt Repayments changed 0.0% year-over-year to $100000.0; the TTM value through Dec 2022 reached $200000.0, down 97.14%, while the annual FY2023 figure was $300000.0, 50.0% up from the prior year.
  • Long-Term Debt Repayments reached $100000.0 in Q4 2022 per EW's latest filing, roughly flat from $100000.0 in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $601.2 million in Q4 2018 and bottomed at -$8.7 million in Q3 2021.
  • Average Long-Term Debt Repayments over 5 years is $65.5 million, with a median of $3.8 million recorded in 2019.
  • Peak YoY movement for Long-Term Debt Repayments: surged 10635.71% in 2018, then tumbled 495.45% in 2021.
  • A 5-year view of Long-Term Debt Repayments shows it stood at $601.2 million in 2018, then tumbled by 99.14% to $5.2 million in 2019, then crashed by 42.31% to $3.0 million in 2020, then crashed by 96.67% to $100000.0 in 2021, then changed by 0.0% to $100000.0 in 2022.
  • Per Business Quant database, its latest 3 readings for Long-Term Debt Repayments were $100000.0 in Q4 2022, $100000.0 in Q2 2022, and $100000.0 in Q4 2021.